Kelsie Marks, Nirav Shah, Ly Pham, Jun Chen, Ian White, Krista Burke, Peter Garrett, Mathieu Marella, Prathap Nagaraja Shastri, Brian Geist, Partha Chowdhury, Vinicius Carreira, Wan Cheung Cheung, Adam Zwolak
{"title":"Bispecific antibodies that engage pIgR enrich in mucosa in cynomolgus monkeys.","authors":"Kelsie Marks, Nirav Shah, Ly Pham, Jun Chen, Ian White, Krista Burke, Peter Garrett, Mathieu Marella, Prathap Nagaraja Shastri, Brian Geist, Partha Chowdhury, Vinicius Carreira, Wan Cheung Cheung, Adam Zwolak","doi":"10.1080/19420862.2026.2743413","DOIUrl":null,"url":null,"abstract":"<p><p>Therapeutic antibodies have limited access to barrier‑protected compartments such as the brain, lung and gastric mucosa, and kidney lumen, constraining their effectiveness in many diseases. Approaches using a bispecific antibody that targets a transcytosing receptor such as the polymeric Ig receptor (pIgR) can result in significant enrichment of IgG-based therapeutics across from blood into mucosal or mucosal lining. The polymeric Ig receptor is expressed in epithelial layers in many tissues, but differences in expression patterns across species represent a challenge in validating preclinical <i>in vivo</i> models. Here, we compare RNA and protein expression across an array of human, cynomolgus monkey, and mouse tissues. We show that pIgR expression in cynomolgus monkeys is similar to expression in humans. We further evaluate the ability of pIgR-targeted bispecific antibodies to transcytose into lung and gastrointestinal mucosa in cynomolgus monkeys. We show that pIgR-targeted bispecific antibodies rapidly deplete from serum, while enriching 5-10-fold in bronchoalveolar lavage fluid compared to normal IgG antibodies. These results support the use of anti-pIgR bispecific antibodies to treat diseases requiring targeting in mucosal areas.</p>","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"18 1","pages":"2743413"},"PeriodicalIF":7.9000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13644599/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mAbs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19420862.2026.2743413","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Therapeutic antibodies have limited access to barrier‑protected compartments such as the brain, lung and gastric mucosa, and kidney lumen, constraining their effectiveness in many diseases. Approaches using a bispecific antibody that targets a transcytosing receptor such as the polymeric Ig receptor (pIgR) can result in significant enrichment of IgG-based therapeutics across from blood into mucosal or mucosal lining. The polymeric Ig receptor is expressed in epithelial layers in many tissues, but differences in expression patterns across species represent a challenge in validating preclinical in vivo models. Here, we compare RNA and protein expression across an array of human, cynomolgus monkey, and mouse tissues. We show that pIgR expression in cynomolgus monkeys is similar to expression in humans. We further evaluate the ability of pIgR-targeted bispecific antibodies to transcytose into lung and gastrointestinal mucosa in cynomolgus monkeys. We show that pIgR-targeted bispecific antibodies rapidly deplete from serum, while enriching 5-10-fold in bronchoalveolar lavage fluid compared to normal IgG antibodies. These results support the use of anti-pIgR bispecific antibodies to treat diseases requiring targeting in mucosal areas.
期刊介绍:
mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.